BPC-157 vs Teduglutide
Side-by-Side Comparison
| Attribute | Bpc 157 | Teduglutide |
|---|---|---|
| Category | Healing & Recovery | Gastrointestinal / GLP-2 Analog |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | Teduglutide binds to the GLP-2 receptor expressed on intestinal subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells. |
| Evidence Rating | C — Phase I–II Clinical Trials | A — FDA Approved |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | FDA-approved (Gattex for SBS, December 2012) |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | Common (>=10%): abdominal pain, nausea, injection site reactions, headache, abdominal distension, upper respiratory tract infection; GI-related: intestinal obstruction, pancreatitis, biliary and pancreatic duct stenosis reported |
| Route | Subcutaneous (preferred), Intramuscular, or Oral | Subcutaneous injection |
| Dose Range | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials | 0.05 mg/kg once daily |
| Frequency | Once daily | Once daily |
| Molecular Weight | ~1419.5 g/mol | ~3752 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | ~2-3 hours |
Overview
BPC-157 and Teduglutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
Teduglutide — Mechanism & Evidence
Teduglutide is a 33-amino-acid recombinant analog of human glucagon-like peptide-2 (GLP-2) (MW ~3752 g/mol) with a single amino acid substitution (Ala2 to Gly) that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation. It was FDA-approved in December 2012 (brand name Gattex in the US, Revestive in Europe) for the treatment of adults with short bowel syndrome (SBS) who are dependent on parenteral support. Teduglutide is the first and only GLP-2 analog approved for this indication.
Key claims: Reduces parenteral nutrition requirements in short bowel syndrome; Enables weaning off parenteral nutrition in some patients; Increases intestinal absorption and villus growth.
Shared Research Applications
These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Teduglutide targets Short Bowel Syndrome, Parenteral Nutrition Reduction, Intestinal Rehabilitation.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Teduglutide: Common (>=10%): abdominal pain, nausea, injection site reactions, headache, abdominal distension, upper respiratory tract infection GI-related: intestinal obstruction, pancreatitis, biliary and pancreatic duct stenosis reported Potential for accelerated neoplastic growth: FDA requires colonoscopy within 6 months before starting and at least every 5 years during treatment
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.
BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair
The BPC-157 and TB-500 peptide blend draws attention in research for potential synergy in tissue repair, angiogenesis, and reducing inflammation. BPC-157, a 15-amino-acid synthetic peptide, interacts with growth factors in preclinical models. TB-500, a 43-amino-acid analog of Thymosin Beta-4, supports cell migration and regeneration. Studies explore their roles in wound healing, tendon recovery, and more.